DXCM News
Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2026 financial results after market close on Thursday, October 29, 2026. Management will hold a conference call to review the company's third quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the...
Business Wire
Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2026 financial results after market close on Thursday, October 29, 2026. Management will hold a conference call to review the company's third quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the...
Business Wire
Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
DEXCOM, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of Dexcom U, the companys one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes.This press release features multimedia. View the full...
Business Wire
DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care
Dexcom sees room to expand CGM adoption as low awareness, reimbursement hurdles and rising GLP-1 use create new opportunities in Type 2 diabetes.
Zacks
Here's Why DexCom (DXCM) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today released its Dexcom State of Type 2 Report: Global Access and Attitudes to Diabetes Technology in advance of the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept...
Business Wire
Dexcom Promotes Jereme Sylvain to Chief Operating Officer
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the promotion of Jereme Sylvain to the role of Chief Operating Officer (COO) in addition to his duties as Chief Financial Officer. In this expanded role, Mr. Sylvain will assume oversight of Dexcoms global...
Business Wire
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and competition risks.
Zacks
Dexcom Appoints Glenn Boehnlein to Board of Directors
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Mr. Boehnlein is a highly accomplished healthcare executive and finance leader with more than 20 years of experience in...
Business Wire
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, Sept. 7, 2026 Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We...
PR Newswire
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks